Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III CONQUER Study for Chronic and Episodic Migraine

 Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III CONQUER Study for Chronic and Episodic Migraine

Shots:

  • The P-III CONQUER study involves assessing of Emgality vs PBO in 462 patients in a ratio (1:1) with chronic and episodic migraine with documented prior failures on two to four SOC migraine preventive medication categories
  • The P-III CONQUER study resulted in meeting its 1EPs & 2EPs i.e, monthly reduction in migraine headache days by (4.1 vs 1.0 days) & 50%, 75% and 100% response rates and improvements in (MSQ-RFR) domain
  • Emgality is a mAb targeting CGRP and has received FDA’s approval for the preventive treatment of migraine in adults in Sept’2018 and for episodic cluster headache in adults in Jun’2019 with an EU’s approval for the prophylaxis of migraine in adults in Nov’2018

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Bolon

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post